MARKETS / NASDAQ / OPRX
NASDAQ · SERVICES-BUSINESS SERVICES, NEC · SMALL CAP

OptimizeRx Corp. OPRX

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$109.4M
▲ 18.8% vs FY2024
EPS · FY25
$0.27
Dividend / sh · FY25
Payout · FY25
ROE · FY25
4.2%
Net margin · FY25
4.7%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 109.4M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.040.080.120.10.0201020132016201920222025
0.040.080.120.10.02016201920222025

5 cents of every revenue dollar became profit this year.

Per share
USD 0.27
Diluted EPS, FY2025
EPS
0.40.81.20.27201020132016201920222025
0.40.81.20.272016201920222025

The company pays no cash dividend.

Profitability
4.2%
Return on equity, FY2025
ROE
2464.2%201020132016201920222025
2464.2%2016201920222025
Operating margin10.7%
Net margin4.7%
Return on assets2.9%

Each USD of equity produced 4 cents of profit this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+20.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+20.6%
+20.4%
+31.2%
+63.1%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.02B
Shares outstanding, FY2025
0.010.02201020132016201920222025
0.030.022016201920222025
Change, 5 years+23.2%
Change, 10 years

The share count grew 23% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 176.9M
total assets, end of FY2025
Total assetsUSD 176.9M
EquityUSD 128.3M
CashUSD 23.4M
Gross debtUSD 25.7M
Net debtUSD 2.3M
Current ratio3.04×

Net debt stands at 2% of equity.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
−0.0
·
·
·
−0.0
·
·
·
0.0
0.0
0.0
·
·
·
Net income $B
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.27
−1.10
−1.03
−0.64
0.02
−0.15
−0.23
0.02
−0.21
−0.05
·
−0.04
−0.02
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
4.2
−16.5
−13.9
−8.9
0.4
−4.7
−9.9
1.8
−30.0
−18.4
−8.8
−32.7
−17.4
−30.4
−121.8
−106.1
Shares out B
0.02
0.02
·
0.02
0.02
0.02
0.01
0.01
0.01
0.03
0.03
0.02
0.01
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
52 of 53
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 1 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed